Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 4 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer... January 10, 2025 How we are working with industry to translate research into real... April 26, 2022 EMA Reminds Physicians to Use Atezolizumab with Nab-paclitaxel for Treating TNBC October 6, 2020 Commemorating the Contributions of Cancer Research Greats March 12, 2021 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma No OS Benefit for Active Maintenance Treatment with Olaparib Relative to... Signal of Increased Risk of Major Cardiovascular Events and Cancer with...
